The pilot program will include select OneTouch patients and track clinical outcomes as well as patients’ experience and satisfaction with the program.
Through this pilot, people with type 2 diabetes using the OneTouch Reveal app, a mobile diabetes management tool that can help people with diabetes remotely track their blood sugar from their wireless device and easily share results with their healthcare team and loved ones, will get free access to OneTouch Reveal and Noom’s Diabetes Management Program, integrated through Apple Health Kit. MALVERN, Pa., / PR Newswire/ - LifeScan, a world leader in blood glucose monitoring and maker of the iconic OneTouch® brand, today announced it is collaborating with Noom®, the world’s leading behavior change company which has been disrupting the weight loss and healthcare industries, on a pilot program integrating its OneTouch Reveal® app with Noom’s digital diabetes and weight loss management program. With Noom’s disruptive AI-driven behavioral health technology Results from the final analysis of all 299 participants as well as key themes from semi-structured interviews with patients will be presented.Pilot will combine LifeScan’s diabetes management experience As compared to matched control patients at non-participating facilities, participants experienced a greater reduction in A1c of 0.1 (p=0.61) at hospital A and 0.7 (p=0.02) at hospital B. Among the first 196 patients enrolled, the mean reduction in A1c from baseline to six months post enrollment was 0.7 at hospital A (n=97) and 1.6 at hospital B (n=97). Of these 137 patients, 52% used the app at least once per week recording blood glucose and medication were the most frequently used features (82% and 62%, respectively). Two hundred ninety-nine patients received the app, and 137 (46%) used the app at least once. Key aims of this pilot program were to: 1) increase patient education and support for diabetes self-management 2) test the use of technology adaptation in a vulnerable patient population and 3) improve diabetes outcomes as measured by reductions in A1c. Participants were able to record and receive feedback on their medications, blood glucose, blood pressure, and meals. The app was provided to patients in English and Spanish. H+H launched a pilot program of BlueStar, an FDA-approved mobile app for diabetes self-management, among patients with poorly controlled type 2 diabetes at two of its acute care hospitals. NYC Health + Hospitals (H+H) is the largest safety net healthcare system in the nation. Additionally, the use of DHTs among diverse, low-income patient populations has not been well studied. Historically, safety net systems have been slow to adopt DHTs, in part due to assumptions about literacy and the use of technology among low-income or non-English speaking patients. In recent years, the use of digital health technologies (DHTs) for chronic disease management has increased, with some facilitating improvements in diabetes outcomes. Institutional Subscriptions and Site Licensesįor patients with type 2 diabetes, self-management remains a significant challenge.Special Edition Series: Disrupting Therapeutic Inertia in Diabetes Management.Special Edition: SGLT2 Inhibitors and Diabetic Kidney Disease.Special Edition Series: SGLT2 Inhibitors in Type 2 Diabetes: Cardiovascular and Renal Outcomes.Special Edition Series: Diabetes and Influenza.Special Edition: Painful Diabetic Peripheral Neuropathy.Special Edition Series: COVID-19 and Diabetes.